Doctor's Guide -- GLASGOW, Scotland -- October 4, 2010 -- Patients with Parkinson's disease who experience wearing-off of efficacy when treated with levodopa/benserazide (LB) or levodopa/carbidopa (LC) benefit significantly from a switch to levodopa/carbidopa/entacapone (LCE), according to findings reported here at the 2nd World Parkinson Congress (WPC).
